share_log

新銳醫藥：須予披露交易 －於江西一脈陽光集團之基石投資

NEW RAY MEDIC: DISCLOSEABLE TRANSACTION -CORNERSTONE INVESTMENT IN JIANGXI RIMAG GROUP

Hong Kong Stock Exchange ·  May 30 06:30
Summary by Futu AI
新銳醫藥國際控股有限公司（新銳醫藥）於2024年5月28日宣布，其全資附屬公司中國新銳與江西一脈陽光集團、中信證券（香港）有限公司及中信里昂證券有限公司簽訂基石投資協議。根據協議，中國新銳將以12,000,000港元認購江西一脈陽光集團的投資者股份，不包括將支付的經紀佣金及徵費。該基石投資因涉及最高百分比率超過5%但少於25%，按照上市規則構成須予披露交易。江西一脈陽光集團為專門從事醫學影像服務的醫療集團，新銳醫藥董事會認為此次投資符合公司多元化發展策略，並有助於為股東帶來長期投資回報。投資完成須待若干先決條件達成，包括相關批准、許可或豁免，以及中國證監會的接受等。若條件未能達成，基石投資協議將終止。新銳醫藥亦同意在上市日期起計十二個月內不出售任何基於協議購買的投資者股份。
新銳醫藥國際控股有限公司（新銳醫藥）於2024年5月28日宣布，其全資附屬公司中國新銳與江西一脈陽光集團、中信證券（香港）有限公司及中信里昂證券有限公司簽訂基石投資協議。根據協議，中國新銳將以12,000,000港元認購江西一脈陽光集團的投資者股份，不包括將支付的經紀佣金及徵費。該基石投資因涉及最高百分比率超過5%但少於25%，按照上市規則構成須予披露交易。江西一脈陽光集團為專門從事醫學影像服務的醫療集團，新銳醫藥董事會認為此次投資符合公司多元化發展策略，並有助於為股東帶來長期投資回報。投資完成須待若干先決條件達成，包括相關批准、許可或豁免，以及中國證監會的接受等。若條件未能達成，基石投資協議將終止。新銳醫藥亦同意在上市日期起計十二個月內不出售任何基於協議購買的投資者股份。
XINROI PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (XINYUI PHARMACEUTICALS) ANNOUNCED ON 28 MAY 2024 THAT ITS WHOLLY OWNED SUBSIDIARIES CHINA XINROI HAVE SIGNED A CORNERSTONE INVESTMENT AGREEMENT WITH JIANGXI SUNSHINE GROUP, CITIC SECURITIES (HONG KONG) LIMITED AND CITIC LION SECURITIES LIMITED. Under the agreement, New China will subscribe for investor shares in Jiangxi Sunshine Group for HKD12,000,000, excluding brokerage commissions and fees to be paid. The cornerstone investment constitutes a disclosable transaction in accordance with the listing rules because it involves a maximum percentage of more than 5% but less than 25%. Jiangxi Yinghua Sunshine Group, a medical group specializing in medical imaging services, believes that this investment is in line with the company's diversified development strategy and will help bring long-term return on investment...Show More
XINROI PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (XINYUI PHARMACEUTICALS) ANNOUNCED ON 28 MAY 2024 THAT ITS WHOLLY OWNED SUBSIDIARIES CHINA XINROI HAVE SIGNED A CORNERSTONE INVESTMENT AGREEMENT WITH JIANGXI SUNSHINE GROUP, CITIC SECURITIES (HONG KONG) LIMITED AND CITIC LION SECURITIES LIMITED. Under the agreement, New China will subscribe for investor shares in Jiangxi Sunshine Group for HKD12,000,000, excluding brokerage commissions and fees to be paid. The cornerstone investment constitutes a disclosable transaction in accordance with the listing rules because it involves a maximum percentage of more than 5% but less than 25%. Jiangxi Yinghua Sunshine Group, a medical group specializing in medical imaging services, believes that this investment is in line with the company's diversified development strategy and will help bring long-term return on investment for shareholders. Investment completion is subject to certain prerequisites, including relevant approvals, permits or exemptions, and acceptance by the China Securities and Exchange Commission, etc. If the conditions are not met, the cornerstone investment agreement will be terminated. Novi Pharmaceuticals also agrees not to sell any investor shares purchased under the agreement for a period of twelve months from the listing date.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.